Last reviewed · How we verify
RO0503821 (1x/4 Weeks)
RO0503821 is a small molecule that targets the S1P1 receptor.
RO0503821 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | RO0503821 (1x/4 Weeks) |
|---|---|
| Also known as | Mircera |
| Sponsor | Hoffmann-La Roche |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the S1P1 receptor, RO0503821 modulates sphingosine-1-phosphate signaling, which plays a crucial role in lymphocyte trafficking and immune responses.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis. (PHASE2)
- A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients (PHASE3)
- A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia. (PHASE2)
- A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia (PHASE2)
- A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia. (PHASE3)
- A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO0503821 (1x/4 Weeks) CI brief — competitive landscape report
- RO0503821 (1x/4 Weeks) updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI